Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes
Sidra Batool, Tiyyaba Furqan, Muhammad Sibte Hasan Mahmood, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 2, pp. 70-79
Open Access | Times Cited: 10

Showing 10 citing articles:

Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease
Honghua Zhang, Yuying Wang, Yuqing Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114606-114606
Closed Access | Times Cited: 52
Dual-Mode Ratiometric Electrochemical and Turn-On Fluorescent Detection of Butyrylcholinesterase Utilizing a Single Probe for the Diagnosis of Alzheimer’s Disease
Hui Dong, Le Zhao, Tao Wang, et al.
Analytical Chemistry (2023) Vol. 95, Iss. 21, pp. 8340-8347
Closed Access | Times Cited: 25
Exploring the intricacies of calcium dysregulation in ischemic stroke: Insights into neuronal cell death and therapeutic strategies
Vikrant Rahi, Ravinder K. Kaundal
Life Sciences (2024) Vol. 347, pp. 122651-122651
Closed Access | Times Cited: 12
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease
Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Lynx1 and the family of endogenous mammalian neurotoxin-like proteins and their roles in modulating nAChR function
Talulla B. Palumbo, Julie M. Miwa
Pharmacological Research (2023) Vol. 194, pp. 106845-106845
Open Access | Times Cited: 8
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease
Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Carltonine-derived compounds for targeted butyrylcholinesterase inhibition
Filip Pidaný, Jana Křoustková, Jaroslav Jenčo, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 5, pp. 1601-1625
Open Access | Times Cited: 1
Gastroretentive Delivery Approach to Address pH-Dependent Degradation of (+)- and (-)-Phenserine
Pratishtha Verma, Leyla Rezaei, Ramprakash Govindarajan, et al.
AAPS PharmSciTech (2024) Vol. 25, Iss. 7
Closed Access
In silico exploration of promising heterocyclic molecules against both acetylcholinesterase and butyrylcholinesterase enzymes
Hai Duc Nguyen, Min‐Sun Kim
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 14, pp. 7128-7149
Open Access | Times Cited: 1
Carltonine-Derived Compounds for Targeted Butyrylcholinesterase Inhibition
Filip Pidaný, Jana Křoustková, Jaroslav Jenčo, et al.
(2023)
Closed Access
Page 1

Scroll to top